Trading Statement

RNS Number : 9675Z
Spire Healthcare Group PLC
16 January 2020
 

Spire Healthcare Group plc

("Spire Healthcare", "the Company" or "the Group")

 

TRADING UPDATE

 

16 January 2020

 

Spire Healthcare Group plc (LSE: SPI), a leading UK independent hospital group, today announces an unaudited trading update for the year ending 31 December 2019.

 

The Group made good progress in FY19 with positive momentum in sales growth, particularly private revenues, and the Board expects adjusted EBITDA pre-IFRS 16 to be in line with guidance and current market expectations.

 

Performance has been underpinned by Spire's continued investment in clinical quality and patient safety which has resulted in 83% of the Company's sites now rated Good or Outstanding by the CQC or equivalent, up from 81% at H1 19 and 76% at FY18.

 

Further progress on cash generation in the second half of 2019 means the Group anticipates a year-end net bank debt position of c.£330m, down from £362.2m at H1 19 and £372.7m at FY18, with capex of c.£60m in-line with prior Company guidance.

 

The Group expects to publish its Preliminary Results for the year ending 31 December 2019 on 5 March 2020.

 

For further information please contact:

 

Spire Healthcare
Cora McCallum, Head of Investor Relations
+44 (0)20 7427 9169

 

Instinctif
Guy Scarborough
+44 (0)20 7457 2020

 

Registered office and head office:

Spire Healthcare Group plc
3 Dorset Rise
London
EC4Y 8EN

 

Registered number 9084066

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTZZGMMMVKGGZG
UK 100

Latest directors dealings